The researchers from Baltimore-based Johns Hopkins compiled a database of 224 digital health companies that had raised at least $2 million in funding and looked into their claims about their products and then tried to match them to clinical trials in which the company was listed as a collaborator. They then used this data to create a clinical robustness score that quantified the amount of clinical evidence for the efficacy of the service.
They found that 44 percent of the digital health startups had no filings for regulatory or clinical trials, giving them a clinical robustness score of zero. Another 15 percent of companies had a robustness score of 1 and 11 percent had a score of 2. There was also a lack of correlation between a company’s venture capital funding and its clinical robustness, suggesting an asymmetry between the two realms.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
